Inter-patients and intra-patient variability of critical organs absorbed doses and haematological changes during ¹⁷⁷Lu-DOTATATE therapy in patients with neuroendocrine tumours. (EANM 2026) - Sep 29, 2026 - Abstract #EP-1008; "[1-3]To evaluate inter-patient variability in absorbed doses to critical organs during 177Lu-DOTATATE therapy and to assess intra-patient, inter-cycle variability in absorbed doses as well as associated haematological changes across successive treatment cycles... In fixed dose protocol significant inter- and intra-patient variability in critical organs absorbed doses, particularly in the liver were observed. It further supports the need for personalized dosimetry and investigation of dose-toxicity relationship in 177Lu-PRRT."
Clinical • Neuroendocrine Tumor • Oncology • Solid Tumor
|
|
M. Poniatowska 1, 2, 3; H. Piwowarska-Bilska 2, 1; A. Marciniak 1; J. Stenka 1; B. Birkenfeld 2, 1
|